HRC Open Innovation Challenge 2026

27 May – 4 Jun 2026 | Barcelona, Spain

THERA65

Start up

www.thera65.comMilan, Italy
8 profile visits

About

Resistance to cancer therapies is the primary cause of limited therapeutic benefit for oncology patients. Current treatment strategies, whether generalized chemotherapy or targeted therapies, often fail due to the development of resistance.

THERA65 is an innovative biotech startup focused on developing personalized diagnostics and therapies for oncology patients. Our technology is based on the groundbreaking discovery of the new biomarker p65BTK, an oncogenic protein expressed in various solid cancer.

Market Target

B2B

Main Sector of Activity (SINGLE CHOICE)

Biotechnology

Field of aplication (Multiple choice)

Pharmaceutics

Representatives

Remote
Remote

CEO

THERA65